Abstract:Purpose/Objective(s) Clinically relevant biomarkers for anti-programmed death (PD)-1 therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) are limited to PD ligand-1 combined proportion score (PD-L1 CPS) on tumor biopsies. Cytokines are soluble proteins that act as a bridge between innate immunity, inflammation, and cancer. Given the interest in circulating biomarkers, this study sought to evaluate pre- and post-treatment serum cytokine expression signatures in R/M HNSCC treated with anti-PD-1 therapy. Materials/Methods In this ongoing, prospective multi-center study, 33 paired pre- and post-treatment (cycle 2 day 1) blood samples were analyzed for 92 cytokine biomarkers (Olink Target 96 Immuno-Oncology) in patients with R/M HNSCC on anti-PD-1-based therapy. Associations between pre-treatment, post-treatment, and change of pre- to post-treatment cytokine levels, overall survival (OS), and progression-free survival (PFS) were assessed using Kaplan-Meier curves, multivariable Cox proportional hazards (adjusted for age, sex, smoking, PD-L1 CPS, ECOG performance status, and platelet count), and unsupervised clustering analyses. Results There was a statistically significant association between pre-treatment cytokine expression signature, and both immune composition (e.g., relative fractions of circulating immune cell subtypes) and platelet count. Comparing pre- and post-treatment samples, expression levels of most cytokines exhibited a statistically significant increase (p <0.05). In pre-treatment samples, several cytokines exhibited nominally statistically significant associations (p < 0.05) with both OS and PFS in multivariable model. Similar results were seen in analyses of serum cytokines with PFS in post-treatment samples. Machine learning analysis using Elastic Net models identified a panel of cytokines (CD40.L, EGF, ANGPT1, MCP.4, CXCL1, IL10) that predicted survival with high prognostic performance (Cross Validated C-index of 0.75) in pre-treatment samples. Notably, a different panel of cytokines (ANGPT1, IL10, FGF2, TNFSF14, Gal.1, HGF, PTN, VEGFA, CCL20) predicted survival with even higher prognostic performance (Cross Validated C-index of 0.90) in post-treatment samples. Unsupervised clustering analysis based on the change in pre- versus post-treatment cytokine expression identified two subgroups which differed in their survival trajectories (log-rank p =0.09 and 0.01 for OS and PFS, respectively), where the subgroup with smaller changes in serum cytokine levels was associated with higher survival. Conclusion Our results highlight the potential prognostic and predictive value of serum cytokine expression signatures in R/M HNSCC treated with anti-PD-1 therapy and underscore the importance of longitudinal on-treatment assessments in peripheral blood.

Suppressive immune profile in combined positive score positive head and neck cancer patients treated with immunotherapy.

The role of CD73 in predicting the response to immunotherapy in head and neck cancer patients

Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on the Cancer Genome Atlas Dataset

Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab

Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients

LAG 3/MHC 2 and PD 1/PD L1 Expression in Non-Small Cell Lung Cancer Patients.

Combined Positive Score and Cisplatin Sensitivity Are Prognostic Factors for Response to Nivolumab Therapy for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck

Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma

B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma

Impact of T Cell Exhaustion and Stroma Senescence on Tumor Cell Biology and Clinical Outcome of Head and Neck Squamous Cell Carcinomas

Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer

Pre- and Post-treatment Serum Cytokine Expression Signatures and Survival Outcomes in Patients with Head and Neck Squamous Cell Cancer on Anti-PD-1 Therapy

Treatment response of advanced HNSCC towards immune checkpoint inhibition is associated with an activated effector memory T cell phenotype

948P Pre-treatment Characteristics and Long-Term Outcomes of Recurrent-Metastatic Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors

A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors

CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line

Abstract 3852: Comprehensive genomic profiling of recurrent or metastatic head and neck cancer presenting with combined positive score 90 or more

Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer

Impact of the tumor proportion score (TPS) and the combined positive score (CPS) on the use of immunotherapy in patients with metastatic non-small cell lung cancer.

The impact of tumor hypoxia on the clinical efficacy of anti-PD-1 mAb treatment in recurrent/metastatic HNSCC patients (R/M).

Analysis of Proliferating Treg Cells As a Predictor for Immunotherapy Response Using Systemic Longitudinal Immune Profiling: Biomarker Analysis of the Phase 3 CONTINUUM Trial.